In time for World Cancer Day, Lightpoint Medical, a medical device company developing miniaturized surgical tools for advanced intra-operative cancer detection, has received CE Mark approval for SENSEI®, the first robotic gamma probe to be commercially available to European hospital system. This is a great achievement as CE marking is an administrative marking that indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area.
SENSEI® has been designed for intra-operative detection of sentinel lymph nodes as well as cancer metastasis through the lymphatic system. The technology promises more precise, targeted cancer surgery and is applicable across a wide range of major cancer types, including lung, colorectal, stomach, gynecological, and prostate cancer.
Dr. David Tuch, CEO of Lightpoint Medical says: “Lightpoint is developing the most advanced intra-operative cancer detection technologies. Securing CE Mark for SENSEI® is an important milestone in our efforts to transform cancer surgery and underscores our commitment to meet surgeons’ needs for miniaturized cancer detection tools as robotic platform technologies grow to dominate surgical practice.
SENSEI® promises accurate real-time cancer detection for robot-assisted cancer surgery. Currently, surgeons have no way to precisely detect cancer intra-operatively. As a result, millions of patients suffer every year as cancer is frequently left behind or healthy, functional tissue is needlessly removed.”Here’s a video from Lightpoint Medical introducing the SENSEI probe:
SENSEI® locates SPECT radioligands such as 99mTc-nano colloid for sentinel lymph node detection or cancer-targeted drugs for cancer metastasis detection such as 99mTc-PSMA (Prostate-Specific Membrane Antigen) in prostate cancer surgery. The CE Mark approval of SENSEI® is for sentinel lymph node detection. The device was successfully registered with the FDA in September 2020.
To learn more please visit: https://lightpointmedical.com/.
Source: Lightpoint Medical, PR Newswire